Sign up to save your podcasts
Or
Share Managing Side Effects of New Treatments for Small Cell Lung Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing Side Effects of New Treatments for Small Cell Lung Cancer
Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments.
We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab.
Key topics covered in this episode:
• Overview of the current treatment landscape and new data from ASCO 2025
• Common side effects associated with lurbinectedin and immunotherapy
• Strategies for managing adverse events, including hematologic toxicities and liver function monitoring
• The role of supportive care and palliative care in enhancing patient quality of life
• Collaboration between community oncologists and academic centers for optimal patient care
Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments.
We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab.
Key topics covered in this episode:
• Overview of the current treatment landscape and new data from ASCO 2025
• Common side effects associated with lurbinectedin and immunotherapy
• Strategies for managing adverse events, including hematologic toxicities and liver function monitoring
• The role of supportive care and palliative care in enhancing patient quality of life
• Collaboration between community oncologists and academic centers for optimal patient care
Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
321 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
290 Listeners
White Coat Investor Podcast
2,430 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
Core IM | Internal Medicine Podcast
1,140 Listeners
The ONS Podcast
200 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Becker’s Healthcare Podcast
188 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners